Genmab A/S ADS GMAB

Genmab A/S es una empresa de biotecnología internacional con sede en Dinamarca. Se especializa en la creación y desarrollo de terapias con anticuerpos para el tratamiento del cáncer. La empresa es la creadora de los anticuerpos aprobados: DARZALEX (daratumumab) para el tratamiento de ciertas indicaciones de mieloma múltiple, Kesimpta para el tratamiento de adultos con formas recurrentes de esclerosis múltiple, TEPEZZA (teprotumumab) para el tratamiento de la enfermedad tiroidea ocular y FASPRO, para el tratamiento de pacientes adultos con ciertas indicaciones de mieloma múltiple. La primera terapia creada por Genmab aprobada, Arzerra, aprobada para el tratamiento de ciertas indicaciones de leucemia linfocítica crónica, está disponible en Japón y también está disponible en otros territorios a través de programas de uso compasivo o acceso oncológico. Genmab desarrolla una amplia cartera de productos clínicos y preclínicos, y posee cuatro tecnologías de anticuerpos, la plataforma bispecífica DuoBody, la plataforma HexaBody, la plataforma DuoHexaBody y la plataforma HexElect.

• The Motley Fool 5 oct

  Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge

  The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.

  

• GlobeNewswire Inc. 5 oct

  Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

  Genmab and AbbVie announced positive Phase 3 trial results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The combination demonstrated a statistically significant 51% reduction in disease progression or death risk compared to R-CHOP alone, with a favorable safety profile. This marks the first Phase 3 study of a bispecific antibody combination to show significant improvement in progression-free survival in frontline DLBCL treatment.

  

• GlobeNewswire Inc. 3 oct

  Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

  Genmab announced Phase 2 results for Rina-S (rinatabart sesutecan) in platinum-resistant ovarian cancer, demonstrating a 45.9% objective response rate with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. The drug showed antitumor activity regardless of folate receptor alpha expression levels, with manageable tolerability. The company is advancing four Phase 3 trials across multiple gynecologic cancers.

  

• GlobeNewswire Inc. 2 oct

  Major Shareholder Announcement

  Darwin Global Management Limited has disclosed a significant shareholding in Genmab A/S, controlling 3,188,361 shares and ADRs representing 5.11% of voting rights as of September 28, 2026. The announcement was made under Danish Capital Markets Act requirements.

  

• GlobeNewswire Inc. 24 sept

  Grant of Restricted Stock Units and Warrants to Employees in Genmab

  Genmab A/S announced the grant of 13,794 restricted stock units and 13,331 warrants to employees. The RSUs have a fair value of DKK 2,268 per unit and will vest after three years, while warrants have an exercise price of DKK 2,268 with a Black-Scholes fair value of DKK 781.96, vesting in three years and expiring after seven years.